In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altimmune Inc.

www.altimmune.com

Latest From Altimmune Inc.

Deal Watch: Altimmune Moves Into NASH With Purchase Of Spitfire

Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.

Deals Business Strategies

Finance Watch: With The Year's Biggest IPO, CFO Says Allogene Is Ready To Go 'Full Throttle'

Allogene launched a $324m IPO to fund development of its allogeneic CAR-T pipeline, bringing its 2018 fundraising total to $744m. Also, GW Pharma's $345m offering tops recent follow-ons.

Financing Business Strategies

Pipeline Watch: Phase III Starts With Murepavadin, CSL112 And Vibegron

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Vaccitech Will Seek Partners For Its Universal Flu Vaccine

Vaccitech's potential universal flu vaccine based on prime-boost technology is in early clinical trials in the UK, with partners likely to be sought for later-stage clinical studies; the company has just raised £20m in a Series A round from private investors that included Google's VC arm, GV, and Sequoia China.

Vaccines Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Vaxin Pharmaceuticals Inc.
  • Vaxin Inc.
  • ImmuneFocus Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Altimmune Inc.
  • Senior Management
  • Vipin K Garg, PhD, Pres. & CEO
    Will Brown, CFO
    Scot Roberts, PhD, CSO
    José Ochoa, CBO
    Bertrand Georges, PhD, CTO
    M. Scott Harris, MD, CMO
  • Contact Info
  • Altimmune Inc.
    Phone: (240) 654-1450
    910 Clopper Rd.
    Ste. 201S
    Gaithersburg, MD 20878
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register